Literature DB >> 14555956

E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models.

Yaohe Wang1, Gunnel Hallden, Richard Hill, Arthi Anand, Ta-Chiang Liu, Jennelle Francis, Gabriel Brooks, Nick Lemoine, David Kirn.   

Abstract

Oncolytic replication-selective adenoviruses constitute a rapidly growing therapeutic platform for cancer. However, the role of the host immune response and the E3 immunoregulatory genes of the human adenovirus were unknown until now. We identified four mouse carcinoma lines of variable permissivity for adenoviral gene expression, cytopathic effects and/or burst size. To determine E3 gene effects in immunocompetent tumor-bearing hosts, we injected tumors with one of three adenoviruses: Ad5 (E3 wild type), dl309 (del. E3 10.4/14.5, 14.7 kDa) or dl704 (del. E3 gp19 kDa). Compared with Ad5 and dl704, dl309 was cleared much more rapidly and/or its activity was lower in all four models. Intratumoral injection with dl309 resulted in markedly greater macrophage infiltration and expression of both tumor necrosis factor and interferon-gamma. Adenovirus replication, CD8(+) lymphocyte infiltration and efficacy were similar upon intratumoral injection with either dl704 or Ad5. E3-dependent differences were not evident in athymic mice. These findings have important implications for the design of oncolytic adenoviruses and may explain the rapid clearance of E3-10.4/14.5,14.7-deleted adenoviruses in patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14555956     DOI: 10.1038/nbt887

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


  58 in total

1.  Lister strain vaccinia virus with thymidine kinase gene deletion is a tractable platform for development of a new generation of oncolytic virus.

Authors:  J Hughes; P Wang; G Alusi; H Shi; Y Chu; J Wang; V Bhakta; I McNeish; A McCart; N R Lemoine; Y Wang
Journal:  Gene Ther       Date:  2015-04-16       Impact factor: 5.250

2.  Verapamil enhances the antitumoral efficacy of oncolytic adenoviruses.

Authors:  Alena Gros; Cristina Puig; Sonia Guedan; Juan José Rojas; Ramon Alemany; Manel Cascallo
Journal:  Mol Ther       Date:  2010-02-23       Impact factor: 11.454

3.  Productive replication of human adenovirus type 5 in canine cells.

Authors:  Vladimir V Ternovoi; Long P Le; Natalya Belousova; Bruce F Smith; Gene P Siegal; David T Curiel
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

4.  Genetic identification of adenovirus type 5 genes that influence viral spread.

Authors:  T Subramanian; S Vijayalingam; G Chinnadurai
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

5.  E1A-expressing adenoviral E3B mutants act synergistically with chemotherapeutics in immunocompetent tumor models.

Authors:  S C Cheong; Y Wang; J-H Meng; R Hill; K Sweeney; D Kirn; N R Lemoine; G Halldén
Journal:  Cancer Gene Ther       Date:  2007-11-23       Impact factor: 5.987

6.  Homologous recombination in E3 genes of human adenovirus species D.

Authors:  Gurdeep Singh; Christopher M Robinson; Shoaleh Dehghan; Morris S Jones; David W Dyer; Donald Seto; James Chodosh
Journal:  J Virol       Date:  2013-09-11       Impact factor: 5.103

7.  Anticancer activity of oncolytic adenovirus vector armed with IFN-alpha and ADP is enhanced by pharmacologically controlled expression of TRAIL.

Authors:  E V Shashkova; M N Kuppuswamy; W S M Wold; K Doronin
Journal:  Cancer Gene Ther       Date:  2007-11-09       Impact factor: 5.987

8.  Targeting the intratumoral dendritic cells by the oncolytic adenoviral vaccine expressing RANTES elicits potent antitumor immunity.

Authors:  Natalia Lapteva; Melissa Aldrich; David Weksberg; Lisa Rollins; Tatiana Goltsova; Si-Yi Chen; Xue F Huang
Journal:  J Immunother       Date:  2009 Feb-Mar       Impact factor: 4.456

9.  Oncolytic Viruses for Cancer Therapy: Overcoming the Obstacles.

Authors:  Han Hsi Wong; Nicholas R Lemoine; Yaohe Wang
Journal:  Viruses       Date:  2010-01       Impact factor: 5.818

10.  Lister strain of vaccinia virus armed with endostatin-angiostatin fusion gene as a novel therapeutic agent for human pancreatic cancer.

Authors:  J R Tysome; A Briat; G Alusi; F Cao; D Gao; J Yu; P Wang; S Yang; Z Dong; S Wang; L Deng; J Francis; T Timiryasova; I Fodor; N R Lemoine; Y Wang
Journal:  Gene Ther       Date:  2009-07-09       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.